Tools
Stock profile

INTUITIVE SURGICAL INC (ISRG)

ISRG · Latest close $420.95 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$420.95
As of Nov 18, 2026
Tracked funds holding
16 of 149
2026 Q2 13F filings
Opened / added
2 / 4
vs previous quarter
Trimmed / exited
13
vs previous quarter

INTUITIVE SURGICAL INC (ISRG) is held by 16 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds opening new positions, 4 funds adding, and 13 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $20.3M sold). Latest close $420.95 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 18, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-20.3M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Edgewood Management · Bristol (John W. Bristol & Co.) · Alphinity Investment Management — 16 tracked funds hold ISRG. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 24 sales ($20.3M). Insider trading

Often held alongside

Travere Therapeutics, Inc. (TVTX) · Affirm Holdings, Inc. (AFRM) · AXON ENTERPRISE, INC. (AXON) · GRACO INC (GGG) · Snap-on Inc (SNA) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Edgewood Management4.28%1,042,949TRIMMED (-33.0%) Q3 filed Nov 12
Bristol (John W. Bristol & Co.)2.27%386,569ADDED (+7.2%) Q3 filed Nov 13
Alphinity Investment Management2.22%334,585TRIMMED (-39.8%) Q3 filed Nov 2
Mirova US2.11%492,324TRIMMED (-3.9%) Q3 filed Nov 5
Sands Capital Management1.85%1,252,424TRIMMED (-5.2%) Q3 filed Nov 13
Polen Capital Management1.53%447,944TRIMMED (-26.2%) Q3 filed Nov 13
OrbiMed Advisors1.16%157,900TRIMMED (-24.3%) Q3 filed Nov 16
Sarasin & Partners1.14%244,426ADDED (+128.2%) Q3 filed Oct 13
Disciplined Growth Investors0.71%106,000TRIMMED (-0.9%) Q3 filed Nov 16
D1 Capital Partners0.66%574,200NEW Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +7.0% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

610.45320.882024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

182025Q1: 16 funds2025Q4: 18 funds2025Q12025Q4

Tracked funds holding this stock, by quarter (2025Q1–2025Q4, 2 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.

All institutions · Form 13F

Institutions holding2,233 of 8,857 filers
Long-only filers among them2,228
Change vs 2026 Q1-22 net · 1,646 entered · 1,668 exited
Shares reported, all filers302,442,187
Reported value, all filers$117.4B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
Revenue · FY2025$10.1B
Net income · FY2025$2.9B
Total assets · FY2025$20.5B
Shares outstanding346,643,718
Market cap (at latest close)$145.9B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 15, 2026.

Short interest

Shares short · Oct 15, 20267,325,463
Share of shares outstanding2.11%
Days to cover4.05

Shares short at recent settlements — Jul 31, 2026: 6.6M · Aug 14, 2026: 7.1M · Aug 31, 2026: 7.7M · Sep 15, 2026: 8.1M · Sep 30, 2026: 7.4M · Oct 15, 2026: 7.3M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 15, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 15, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 24 sales by 6 insiders ($20.3M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 18, 2026Brosius MarkEVP & Chief Mfg and Supply ChaSell46$430.63$19.8KSEC filing
Nov 17, 2026Brosius MarkEVP & Chief Mfg and Supply ChaSell46$437.33$20.1KSEC filing
Nov 16, 2026Brosius MarkEVP & Chief Mfg and Supply ChaSell46$444.38$20.4KSEC filing
Nov 10, 2026LOEB GARYEVP & Chief Legal and ComplianSell400$458.15$183.3KSEC filing
Nov 4, 2026GUTHART GARY SSell10,000$457.34$4.6MSEC filing
Nov 4, 2026BARRATT CRAIG HSell1,150$460.00$529.0KSEC filing
Oct 30, 2026Brosius MarkEVP & Chief Mfg and Supply ChaSell63$453.60$28.6KSEC filing
Oct 30, 2026Widman FredrikVP Corporate ControllerSell5,448$436.06$2.4MSEC filing
Oct 29, 2026Brosius MarkEVP & Chief Mfg and Supply ChaSell61$447.85$27.3KSEC filing
Oct 28, 2026Brosius MarkEVP & Chief Mfg and Supply ChaSell61$441.60$26.9KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 15, 2026FREDRIK WIDMANOfficer2,178$823.2KSep 15, 2026SEC filing
Sep 8, 2026MARK BROSIUSOfficer694$254.5KSep 8, 2026SEC filing
Aug 11, 2026GUTHART FAMILY TRUSTDirector20,095$7.9MAug 11, 2026SEC filing
Aug 10, 2026AMY L LADDDirector472$178.8KAug 10, 2026SEC filing
Aug 10, 2026GARY LOEBOfficer400$151.5KAug 10, 2026SEC filing
Jun 10, 2026GARY LOEBOfficer400$170.6KJun 10, 2026SEC filing
Jun 8, 2026MARK BROSIUSOfficer665$280.7KJun 8, 2026SEC filing
Jun 3, 2026AMAL JOHNSONDirector12,472$5.0MJun 3, 2026SEC filing
Jun 1, 2026IMAN JEDDIOfficer5,625$2.4MJun 1, 2026SEC filing
May 11, 2026GARY LOEBOfficer400$180.0KMay 11, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Apr 30, 2026Vanguard Capital ManagementSC 13G26,601,4197.5%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 149 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (126), Medicare/Medicaid (63), Medical/Disease Research/Clinical Labs (52).

Federal contracts: $315.5M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$63.3M
FY2022$79.4M
FY2023$58.6M
FY2024$92.5M
FY2025$21.9M
FY2026$-230.1K

Largest awards collected

Award IDAgencyAmountStart
36C10G24K0080Department of Veterans Affairs$48.1MJul 1, 2022
36C10G22K0049Department of Veterans Affairs$32.4MJul 31, 2022
36C10G25K0068Department of Veterans Affairs$14.4MMar 1, 2024
36C25220N0226Department of Veterans Affairs$3.7MMar 10, 2020
36C24624N1156Department of Veterans Affairs$2.8MSep 17, 2024

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Graham — Sound finances and a long run of profits

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

· Earnings Stability — Small earnings swings and almost no loss years

Key figures

· Growth — Latest revenue: $10.1B · 5-yr revenue CAGR: 18.2% · Straight growth years: 5

· Graham — Current ratio: 4.87 · Straight profitable years: 19 · Debt ratio: 0.14 · Latest net income: $2.9B

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.04 · Operating cash flow: $3.0B · Net income: $2.9B

· Earnings Stability — Earnings variation (CV): 0.44 · Loss years (of 10): 0 · Latest net income: $2.9B

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Super-investor 13F BEST — appeared in 2 of the last 40 quarterly lists; latest 2025 Q4, ranked #45 of 50.

· Politician BEST — appeared in 4 of the last 20 quarterly lists; latest 2024 Q2, ranked #14 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together20.0%-21.0%-6.4%-14.6%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold ISRG — ranked by lift, the co-holding pattern described in Methodology: Travere Therapeutics, Inc. (TVTX) · Affirm Holdings, Inc. (AFRM) · AXON ENTERPRISE, INC. (AXON) · GRACO INC (GGG) · Snap-on Inc (SNA) · CHIPOTLE MEXICAN GRILL INC (CMG) · KIMBERLY CLARK CORP (KMB) · BOSTON SCIENTIFIC CORP (BSX).

Filings audit: every filing lens on INTUITIVE SURGICAL INC (ISRG), scored — GetCoattail Research.

Recent 8-K filings

FiledItemsSource
Nov 2, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Oct 20, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jul 27, 20265.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Travere Therapeutics, Inc. (TVTX) · Filings audit: every filing lens on INTUITIVE SURGICAL INC (ISRG), scored · Practice timing on ISRG

One email a week: the week’s new filings and research. Subscribe free

← IRTC  ·  IT →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.